[Primary retroperitoneal pure choriocarcinoma]. 1995

Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
Department of Urology, Cancer Institute Hospital, Tokyo, Japan.

A thirty-year-old clerk presented with a history of left supraclavicular lymph node swelling of a month duration and newly detected multiple lung and mediastinal tumors. Abdominal computed tomography showed two retroperitoneal masses, but no abnormality in both testes was found by physical and ultrasonographic examination. Biopsy of supraclavicular lymph nodes revealed pure choriocarcinoma. Furthermore, beta-subunit of human chorionic gonadotropin was elevated up to 700 ng/ml but alfafetoprotein was normal, resulting in the diagnosis of primary retroperitoneal pure choriocarcinoma. Two cycles of combination chemotherapy with etoposide (VP-16), ifosfamide and cisplatin (VIP) was given and followed by bleomycin, etoposide and cisplatin (BEP) (2 cycles) because of cystitis symptom due to ifosfamide. Since post chemotherapeutic evaluation revealed only partial response, we surgically removed all residual masses in the lung, mediastinum and retroperitoneum, which histologically proved to be necrotic fibrous tissue. He has remained disease-free 15 months after surgery without additional therapy. In order to improve prognosis of primary retroperitoneal pure choriocarcinoma, intense chemotherapeutic regimen like VIP should be given, regularly repeated and followed by aggressive surgical resection of residual masses.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008297 Male Males
D002822 Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL). Choriocarcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012186 Retroperitoneal Neoplasms New abnormal growth of tissue in the RETROPERITONEAL SPACE. Neoplasm, Retroperitoneal,Neoplasms, Retroperitoneal,Retroperitoneal Neoplasm
D018572 Disease-Free Survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. Survival, Disease-Free,Disease Free Survival,Survival, Disease Free

Related Publications

Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
September 1988, Cancer,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
January 1973, Zentralblatt fur allgemeine Pathologie u. pathologische Anatomie,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
April 1992, Pathology, research and practice,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
January 1990, Gynecologic and obstetric investigation,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
June 2004, AJR. American journal of roentgenology,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
March 2023, Asian journal of surgery,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
January 1989, Actas urologicas espanolas,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
January 2010, Indian journal of pathology & microbiology,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
August 1990, Scottish medical journal,
Y Okubo, and I Fukui, and Y Sakano, and K Yoshimura, and H Maeda, and J Yonese, and T Yamauchi, and T Kawai, and S Okumura, and Y Ishikawa
March 2019, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Copied contents to your clipboard!